Related Experiment Video
Updated: Jun 18, 2025
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
10.4K
Errata: B-Type Natriuretic Peptide Inhibits the Expression and Function of SERCA2a in Heart Failure
International Heart Journal
|July 31, 2024
Insights
B-Type Natriuretic Peptide (BNP) was found to inhibit Sarco/Endoplasmic Reticulum Ca2+-ATPase 2a (SERCA2a) expression and function in heart failure. This finding impacts understanding of cardiac muscle calcium handling in this condition.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Heart failure is characterized by impaired cardiac contractility.
- Sarco/Endoplasmic Reticulum Ca2+-ATPase 2a (SERCA2a) is crucial for cardiac muscle relaxation by pumping calcium into the sarcoplasmic reticulum.
- B-Type Natriuretic Peptide (BNP) is a hormone released in response to cardiac stress.
Purpose of the Study:
- To investigate the effect of B-Type Natriuretic Peptide (BNP) on the expression and function of SERCA2a in the context of heart failure.
- To elucidate the molecular mechanisms by which BNP influences SERCA2a activity.
Main Methods:
- Utilized molecular biology techniques to assess SERCA2a expression levels.
- Employed biochemical assays to measure SERCA2a enzyme activity.
- Investigated the impact of BNP treatment on cardiac tissue samples from heart failure models.
Main Results:
- BNP significantly inhibited the expression of SERCA2a in heart failure models.
- BNP reduced the functional activity of SERCA2a, impairing calcium reuptake.
- These effects were linked to specific molecular signaling pathways.
Conclusions:
- B-Type Natriuretic Peptide (BNP) plays a detrimental role in heart failure by suppressing SERCA2a expression and function.
- Inhibition of SERCA2a by BNP contributes to impaired cardiac relaxation and exacerbates heart failure.
- Targeting the interaction between BNP and SERCA2a may offer novel therapeutic strategies for heart failure.
Abstract:
Several errors (shown with underlines) in the following list appeared in the article "B-Type Natriuretic Peptide Inhibits the Expression and Function of SERCA2a in Heart Failure" by Yuting Zhai, Junhong Chen, Rongsheng Kan, Haochen Xuan, Chaofan Wang, Dongye Li, Tongda Xu (Vol. 65 No.2, 292-299, 2024).
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:22Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
578
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
578
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
674
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
674
01:22Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332